Literature DB >> 25595788

Deficiency of antigen-specific B cells results in decreased Trypanosoma cruzi systemic but not mucosal immunity due to CD8 T cell exhaustion.

Nicole L Sullivan1, Christopher S Eickhoff2, John Sagartz3, Daniel F Hoft4.   

Abstract

Vaccines against mucosally invasive, intracellular pathogens must induce a myriad of immune responses to provide optimal mucosal and systemic protection, including CD4(+) T cells, CD8(+) T cells, and Ab-producing B cells. In general, CD4(+) T cells are known to provide important helper functions for both CD8(+) T cell and B cell responses. However, the relative importance of CD4(+) T cells, CD8(+) T cells, and B cells for mucosal protection is less clearly defined. We have studied these questions in detail using the murine model of Trypanosoma cruzi infection. Despite our initial hypothesis that mucosal Abs would be important, we show that B cells are critical for systemic, but not mucosal, T. cruzi protective immunity. B cell-deficient mice developed normal levels of CD8(+) effector T cell responses early after mucosal T. cruzi infection and T. cruzi trans-sialidase vaccination. However, after highly virulent systemic challenge, T. cruzi immune mice lacking T. cruzi-specific B cells failed to control parasitemia or prevent death. Mechanistically, T. cruzi-specific CD8(+) T cells generated in the absence of B cells expressed increased PD-1 and Lag-3 and became functionally exhausted after high-level T. cruzi systemic challenge. T. cruzi immune serum prevented CD8(+) T cell functional exhaustion and reduced mortality in mice lacking B cells. Overall, these results demonstrate that T. cruzi-specific B cells are necessary during systemic, but not mucosal, parasite challenge.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25595788      PMCID: PMC4324165          DOI: 10.4049/jimmunol.1303163

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  B cells and antibodies are required for resistance to the parasitic gastrointestinal nematode Trichuris muris.

Authors:  N M Blackwell; K J Else
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

2.  Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.

Authors:  Rachael D Aubert; Alice O Kamphorst; Surojit Sarkar; Vaiva Vezys; Sang-Jun Ha; Daniel L Barber; Lilin Ye; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

3.  Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen.

Authors:  Daniel F Hoft; Chris S Eickhoff
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Protective intestinal anti-rotavirus B cell immunity is dependent on alpha 4 beta 7 integrin expression but does not require IgA antibody production.

Authors:  N A Kuklin; L Rott; N Feng; M E Conner; N Wagner; W Müller; H B Greenberg
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

5.  Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection.

Authors:  O K Giddings; C S Eickhoff; T J Smith; L A Bryant; D F Hoft
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

6.  Trypanosoma cruzi infection in MHC-deficient mice: further evidence for the role of both class I- and class II-restricted T cells in immune resistance and disease.

Authors:  R L Tarleton; M J Grusby; M Postan; L H Glimcher
Journal:  Int Immunol       Date:  1996-01       Impact factor: 4.823

7.  Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein.

Authors:  V L Pereira-Chioccola; F Costa; M Ribeirão; I S Soares; F Arena; S Schenkman; M M Rodrigues
Journal:  Parasite Immunol       Date:  1999-02       Impact factor: 2.280

8.  Gastric invasion by Trypanosoma cruzi and induction of protective mucosal immune responses.

Authors:  D F Hoft; P L Farrar; K Kratz-Owens; D Shaffer
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

9.  Requirement of B cells for generating CD4+ T cell memory.

Authors:  Jason K Whitmire; Mary S Asano; Susan M Kaech; Surojit Sarkar; Lynn G Hannum; Mark J Shlomchik; Rafi Ahmed
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

10.  Pathogen-induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8+ T-cell response: reversal by adenoviral vaccine.

Authors:  José Ronnie Vasconcelos; Oscar Bruña-Romero; Adriano F Araújo; Mariana R Dominguez; Jonatan Ersching; Bruna C G de Alencar; Alexandre V Machado; Ricardo T Gazzinelli; Karina R Bortoluci; Gustavo P Amarante-Mendes; Marcela F Lopes; Mauricio M Rodrigues
Journal:  PLoS Pathog       Date:  2012-05-17       Impact factor: 6.823

View more
  18 in total

1.  Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.

Authors:  Natacha Cerny; Andrés Sánchez Alberti; Augusto E Bivona; Mauricio C De Marzi; Fernanda M Frank; Silvia I Cazorla; Emilio L Malchiodi
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

Review 2.  Immunity and immune modulation in Trypanosoma cruzi infection.

Authors:  Fabíola Cardillo; Rosa Teixeira de Pinho; Paulo Renato Zuquim Antas; José Mengel
Journal:  Pathog Dis       Date:  2015-10-04       Impact factor: 3.166

Review 3.  CD8+ T cells in Trypanosoma cruzi infection.

Authors:  Rick L Tarleton
Journal:  Semin Immunopathol       Date:  2015-04-29       Impact factor: 9.623

4.  An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8(+) T cell epitopes.

Authors:  Christopher S Eickhoff; Daniel Van Aartsen; Frances E Terry; Sheba K Meymandi; Mahmoud M Traina; Salvador Hernandez; William D Martin; Leonard Moise; Annie S De Groot; Daniel F Hoft
Journal:  Hum Vaccin Immunother       Date:  2015-06-24       Impact factor: 3.452

Review 5.  Understanding CD8+ T Cell Immunity to Trypanosoma cruzi and How to Improve It.

Authors:  Eva V Acosta Rodríguez; Cintia L Araujo Furlan; Facundo Fiocca Vernengo; Carolina L Montes; Adriana Gruppi
Journal:  Trends Parasitol       Date:  2019-10-10

6.  Th17 Cells Provide Mucosal Protection against Gastric Trypanosoma cruzi Infection.

Authors:  Catherine W Cai; Christopher S Eickhoff; Krystal A Meza; Jennifer R Blase; Rebecca E Audette; David H Chan; Kevin A Bockerstett; Richard J DiPaolo; Daniel F Hoft
Journal:  Infect Immun       Date:  2021-06-16       Impact factor: 3.441

7.  Costimulatory Effects of an Immunodominant Parasite Antigen Paradoxically Prevent Induction of Optimal CD8 T Cell Protective Immunity.

Authors:  Christopher S Eickhoff; Xiuli Zhang; Jose R Vasconcelos; R Geoffrey Motz; Nicole L Sullivan; Kelly O'Shea; Nicola Pozzi; David W Gohara; Jennifer R Blase; Enrico Di Cera; Daniel F Hoft
Journal:  PLoS Pathog       Date:  2016-09-19       Impact factor: 6.823

Review 8.  The Unsolved Jigsaw Puzzle of the Immune Response in Chagas Disease.

Authors:  Gonzalo R Acevedo; Magalí C Girard; Karina A Gómez
Journal:  Front Immunol       Date:  2018-08-24       Impact factor: 7.561

9.  Highly competent, non-exhausted CD8+ T cells continue to tightly control pathogen load throughout chronic Trypanosoma cruzi infection.

Authors:  Angela D Pack; Matthew H Collins; Charles S Rosenberg; Rick L Tarleton
Journal:  PLoS Pathog       Date:  2018-11-12       Impact factor: 6.823

10.  Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection.

Authors:  Andrés Sanchez Alberti; Augusto E Bivona; Natacha Cerny; Kai Schulze; Sebastian Weißmann; Thomas Ebensen; Celina Morales; Angel M Padilla; Silvia I Cazorla; Rick L Tarleton; Carlos A Guzmán; Emilio L Malchiodi
Journal:  NPJ Vaccines       Date:  2017-04-10       Impact factor: 7.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.